KT, a South Korean telecommunications giant, said it will invest $2 million (2.7 billion won) in Sonde Health, an American voice biomarker development company, and start business cooperation.
As part of the deal, KT plans to use Sonde Health’s technology to upgrade its AI-based businesses such as call centers and AI speakers. KT has regularly secured voice-based technologies such as AI solutions to diagnose dysphagia, a disorder where patients have difficulty swallowing.
In addition, KT plans to apply voice biomarker technology to telemedicine services promoted in Vietnam, a company official said.
KT’s partner, Sonde Health, specializes in technology that predicts various diseases like mental health and respiratory disorders using voice biomarkers. Voice biomarkers are indicators that can monitor bodily conditions and predict disease by analyzing subtle changes such as voice strength, vocal cord size and movement.
In the same way that sore throats lead to voice changes, a wider range of voice biomarkers will also be applied to diagnose other diseases.
Probe Health is the world’s largest company with health data using voice changes, which is core to the development of voice biomarkers and has global networks with Qualcomm and GN Group.
According to Coherent Market Insights, the global voice biomarker market size is expected to reach approximately 600 trillion won in 2027 with an average annual growth rate (CAGR) of 15.5%. Voice biomarkers are in the spotlight as an ancillary means of patient monitoring as the infrastructure for using voice technologies such as smartphones has grown and remote treatment has increased with Covid-19.
Probe Health is KT’s second strategic overseas investment in digital health, following KT’s investment in NeuroSigma, an American electronic drug development company, earlier this year.
“KT is pursuing various voice-based businesses, so we expect there will be great potential to connect with voice biomarker technology,” said Song Jae-ho, vice president of AI/Business Division. DX Convergence by KT. “Based on Sonde Health’s excellent technological competitiveness, we will promote synergy with KT’s domestic and overseas business. »
Sonde Health CEO David Liu also expressed his delight in showcasing Sonde’s voice biomarker technology with Korea’s leading digital platform company. KT.